EntryPoint Capital LLC Invests $614,000 in Bicycle Therapeutics plc (NASDAQ:BCYC)

EntryPoint Capital LLC bought a new stake in Bicycle Therapeutics plc (NASDAQ:BCYC) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 43,873 shares of the company’s stock, valued at approximately $614,000. EntryPoint Capital LLC owned about 0.06% of Bicycle Therapeutics at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BCYC. Westfield Capital Management Co. LP lifted its stake in shares of Bicycle Therapeutics by 21.5% during the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after buying an additional 327,089 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Bicycle Therapeutics by 33.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after purchasing an additional 32,313 shares in the last quarter. FMR LLC purchased a new position in shares of Bicycle Therapeutics during the 3rd quarter valued at approximately $3,406,000. Erste Asset Management GmbH purchased a new position in Bicycle Therapeutics during the third quarter valued at $325,000. Finally, HighVista Strategies LLC boosted its holdings in Bicycle Therapeutics by 9.7% in the 3rd quarter. HighVista Strategies LLC now owns 139,544 shares of the company’s stock worth $3,158,000 after buying an additional 12,289 shares during the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

BCYC stock opened at $9.20 on Tuesday. The company has a market cap of $636.66 million, a price-to-earnings ratio of -2.80 and a beta of 1.12. The company has a fifty day moving average price of $11.74 and a 200 day moving average price of $17.91. Bicycle Therapeutics plc has a 12 month low of $8.88 and a 12 month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.47 million. During the same period in the prior year, the company earned ($1.16) earnings per share. The business’s revenue was down 30.2% compared to the same quarter last year. As a group, analysts anticipate that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Kevin Lee sold 9,038 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the completion of the sale, the chief executive officer now owns 495,026 shares in the company, valued at approximately $6,974,916.34. This trade represents a 1.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Santiago Arroyo sold 4,943 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $69,646.87. Following the transaction, the insider now owns 69,057 shares in the company, valued at approximately $973,013.13. This trade represents a 6.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,677 shares of company stock valued at $392,413. 8.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a report on Tuesday, March 11th. B. Riley dropped their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Stephens reaffirmed an “equal weight” rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Finally, JMP Securities lowered their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.14.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.